Lot-to-lot Consistency of Quadrivalent Influenza Vaccine (Split Virion), Inactivated

Exclusion Criteria

• •Received seasonal influenza vaccine for 2022-2023 influenza season, or had an influenza vaccine schedule during the study;
• •Suffering from seasonal influenza in the past 6 moths;
• •Women of childbearing age (menarche to premenopause) are pregnant(including positive urine pregnancy test), breastfeeding or planning pregnancy within 1 month;
• •Patients with fever on the day of vaccination,underarm body temperature\>37.2 ℃;
• •History of asthma, allergy to vaccines or vaccine components, and serious adverse reactions to vaccines, such as urticaria, dyspnea, and angioneurotic edema;
• •Congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc.
• •Severe chronic diseases,such as severe cardiovascular diseases, hypertension(Systolic blood pressure ≥140mmHg and/or diastolic blood pressure ≥90mmHg) and diabetes that cannot be controlled by drugs, liver or kidney diseases,malignant tumors, etc.;
• •Severe neurological disease (epilepsy, convulsions or convulsions) or mental illness;
• •Autoimmune disease or immune deficiency/immunosuppression;
• •Thyroid disease or history of thyroidectomy,absence of spleen, functional functional asplenia,and absence of spleen or splenectomy as a result of any condition;
• •Diagnosed abnormal blood coagulation function (eg, lack of blood coagulation factors, blood coagulopathy, abnormal platelets) or obvious bruising or blood coagulation;
• •Immunosuppressive therapy, cytotoxic therapy, inhaled corticosteroids(excluding allergic rhinitis corticosteroid spray therapy, acute noncomplicated dermatitis superficial corticosteroid therapy) in the past 6 months;
• •A long history of alcohol or drug abuse;
• •Onset of various acute or chronic diseases within 7 days prior to the study;
• •Receipt of blood products within in the past 3 months;
• •Receipt of other investigational drugs within 30 days prior to receiving the investigational vaccine;
• •Receipt of attenuated live vaccines or COVID-19 vaccines in the past 14 days,receipt of inactivated or subunit vaccines in the past 7 days;
• •The subjects participated in other clinical trials during the follow-up period or will be planned to participate other clinical trials during the follow-up period;
• •According to the investigator's judgment, the subject has any other factors that are not suitable for participating in the clinical trial.